CSE:AGN - Post Discussion
Post by
SkywalkerofLuke on Mar 07, 2023 3:39pm
Recent News
AGN announced last week that its subsidiary Algernon NeuroScience appointed Dr. David L. Brody as a consultant for its clinical research program for the treatment of Traumatic Brain Injury with DMT.
Key highlights
- Washington University site director for the National Football League (NFL) Neurological player care program
- Board-certified neurologist with both a research and a clinical specialization in TBI and neurodegenerative diseases
- Professor of Neurology at the Washington University School of Medicine in St. Louis
AGN Neuro is planning to be the first company globally to investigate DMT for TBI in humans and is working towards a Phase 2 clinical trial in Q4.
https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/177/algernon-neuroscience-appoints-global-tbi-expert-and-former
Be the first to comment on this post